Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.67M | $-17.61M | $-0.46 |
| 2024 | $103.2K | $-33.42M | $-0.95 |
| 2023 | $18.11M | $-18.95M | $-0.55 |
| 2022 | $9.29M | $-79.97M | $-2.31 |
| 2021 | $10.18M | $-73.18M | $-2.29 |
Social Signal Score
Earnings
Wed, Mar 31(in 8 months)
Consensus estimate $-0.23 per share
Typical surprise +42.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.23 vs $-0.23beat
- Wed, Apr 1$-0.07 vs $-0.28beat
- Mon, Mar 23$-0.11 vs $-0.19beat
- Tue, Aug 12$-0.23 vs $-0.32beat
- Mon, Mar 24$-0.55 vs $-0.33miss
- Thu, Jul 25$-0.19 vs $-0.41beat
Estimates and results for ADAG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ADAGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·3d ago·Neutral
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established
View source ↗